Many Biotechs Have Net Assets That Top Their Market Values
- Order Reprints
- Print Article
Atea Pharmaceuticals a biotech working to develop antiviral treatments for Covid-19 and hepatitis C, might be worth more dead than alive.
Already a subscriber? Sign In